MX2010000981A - Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune. - Google Patents
Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune.Info
- Publication number
- MX2010000981A MX2010000981A MX2010000981A MX2010000981A MX2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A MX 2010000981 A MX2010000981 A MX 2010000981A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibiting
- immune responses
- antibodies
- inhibiting immune
- cd200r
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 5
- 230000028993 immune response Effects 0.000 title abstract 2
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 abstract 2
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96202207P | 2007-07-25 | 2007-07-25 | |
| PCT/US2008/009037 WO2009014745A1 (en) | 2007-07-25 | 2008-07-25 | Antibodies to cd200 and uses thereof in inhibiting immune responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010000981A true MX2010000981A (es) | 2010-05-21 |
Family
ID=40001380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010000981A MX2010000981A (es) | 2007-07-25 | 2008-07-25 | Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8252285B2 (enExample) |
| EP (1) | EP2178561A1 (enExample) |
| JP (4) | JP2010534243A (enExample) |
| KR (1) | KR20100041849A (enExample) |
| AU (1) | AU2008279619B2 (enExample) |
| BR (1) | BRPI0814644A2 (enExample) |
| CA (1) | CA2697159C (enExample) |
| MX (1) | MX2010000981A (enExample) |
| WO (1) | WO2009014745A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534243A (ja) * | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Cd200に対する抗体および免疫応答への使用 |
| MX2012009321A (es) * | 2010-02-11 | 2012-11-21 | Alexion Pharma Inc | Metodos terapeuticos que utilizan anticuerpos anti-cd200. |
| JP6150734B2 (ja) * | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 同種移植片の生存を長期化するための抗cd200抗体の使用 |
| EP3150632B1 (en) | 2011-06-10 | 2020-04-08 | Her Majesty The Queen in right of Canada, as represented by the Minister of National Defence | Anti-ricin antibodies and uses thereof |
| ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
| US9737598B2 (en) * | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| US10888609B2 (en) | 2015-11-03 | 2021-01-12 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2018102594A1 (en) * | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
| KR101968246B1 (ko) * | 2017-04-27 | 2019-04-11 | 서울대학교산학협력단 | 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법 |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| EP3911357A1 (en) | 2019-01-14 | 2021-11-24 | Regents of the University of Minnesota | Cd200ar ligands for cancer immunotherapy |
| EP4296280A1 (en) * | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| DK1032662T3 (da) * | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| WO2004060295A2 (en) | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| NZ599035A (en) * | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| CA2694121C (en) | 2007-07-25 | 2016-06-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Cd200に対する抗体および免疫応答への使用 |
-
2008
- 2008-07-25 JP JP2010518230A patent/JP2010534243A/ja active Pending
- 2008-07-25 EP EP08794745A patent/EP2178561A1/en not_active Withdrawn
- 2008-07-25 BR BRPI0814644-6A2A patent/BRPI0814644A2/pt not_active IP Right Cessation
- 2008-07-25 US US12/670,379 patent/US8252285B2/en not_active Ceased
- 2008-07-25 US US14/080,457 patent/USRE46323E1/en not_active Expired - Fee Related
- 2008-07-25 AU AU2008279619A patent/AU2008279619B2/en not_active Ceased
- 2008-07-25 MX MX2010000981A patent/MX2010000981A/es active IP Right Grant
- 2008-07-25 KR KR1020107003921A patent/KR20100041849A/ko not_active Abandoned
- 2008-07-25 WO PCT/US2008/009037 patent/WO2009014745A1/en not_active Ceased
- 2008-07-25 CA CA2697159A patent/CA2697159C/en not_active Expired - Fee Related
-
2012
- 2012-06-26 US US13/533,546 patent/US8637014B2/en active Active
-
2013
- 2013-05-27 JP JP2013110577A patent/JP5926702B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-07 JP JP2015135830A patent/JP2015172090A/ja active Pending
-
2016
- 2016-03-16 JP JP2016052050A patent/JP2016117762A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20100291085A1 (en) | 2010-11-18 |
| USRE46323E1 (en) | 2017-02-28 |
| US8637014B2 (en) | 2014-01-28 |
| WO2009014745A1 (en) | 2009-01-29 |
| US8252285B2 (en) | 2012-08-28 |
| CA2697159A1 (en) | 2009-01-29 |
| JP5926702B2 (ja) | 2016-05-25 |
| JP2010534243A (ja) | 2010-11-04 |
| AU2008279619B2 (en) | 2013-11-14 |
| JP2016117762A (ja) | 2016-06-30 |
| BRPI0814644A2 (pt) | 2015-01-27 |
| KR20100041849A (ko) | 2010-04-22 |
| CA2697159C (en) | 2017-02-14 |
| EP2178561A1 (en) | 2010-04-28 |
| AU2008279619A1 (en) | 2009-01-29 |
| US20120321625A1 (en) | 2012-12-20 |
| JP2013163695A (ja) | 2013-08-22 |
| JP2015172090A (ja) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010000981A (es) | Anticuerpos para cd200 y usos de los mismos para inhibir respuestas inmune. | |
| MY161909A (en) | Anti-her3 antibodies and uses thereof | |
| HUS1800021I1 (hu) | Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások | |
| GB0515353D0 (en) | Food | |
| PH12013502230A1 (en) | Multispecific antibodies | |
| SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| UA104459C2 (uk) | Антитіла проти fgfr3 і способи їх застосування | |
| MY159679A (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| MY160736A (en) | Bivalent, bispecific antibodies | |
| MX2010007767A (es) | Anticuerpos manipulados con cisteina para conjugacion especifica de sitio. | |
| MY154956A (en) | Chimeric adenoviral vectors | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
| MX339015B (es) | Anticuerpos que se fijan a tweak. | |
| IL188421A0 (en) | Anti-il-23 antibodies, compositions, methods and uses | |
| MX2009003774A (es) | Anticuerpos para linfotoxina-alfa. | |
| MY173526A (en) | Novel anti-?5?1 antibodies and uses thereof | |
| PH12013500933A1 (en) | Methods and compositions for neural disease immunotherapy | |
| MX2009006879A (es) | Anticuerpos contra el cd200r. | |
| MX2010000979A (es) | Metodos y composiciones para tratar enfermedad autoinmune. | |
| MX2009013170A (es) | Particulas de silice y metodos para prepararlas y utilizarlas. | |
| TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |